222P - Effectiveness and tolerability of Nimotuzumab in Locally Advanced or Recurrent /Metastatic Esophageal Cancer: An Indian tertiary care hospital base...

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Anticancer Agents
Oesophageal Cancer
Gastrointestinal Cancers
Biological Therapy
Presenter Nithya Sridharan
Citation Annals of Oncology (2017) 28 (suppl_10): x57-x76. 10.1093/annonc/mdx660
Authors S. Subramanian1, N. Sridharan1, V. Balasundaram2, S. Chaudhari3, D. Pawar3
  • 1Medical Oncology, VS Hospitals & Madras Cancer Institute, 600031 - Chennai/IN
  • 2Radiation Oncology, VS Hospitals & Madras Cancer Institute, 600031 - Chennai/IN
  • 3Medical Affairs, Biocon Limited, 560100 - Bangalore/IN



Esophageal cancer is an aggressive cancer associated with dismal treatment outcomes despite recent advances in surgical techniques, chemotherapy and radiotherapy. Nimotuzumab is an anti-EGFR humanized monoclonal antibody which has been approved for head and neck cancer in India and 20 other countries, and has shown promising results in various solid tumors associated with high EGFR expression. However, there exists a paucity of data on the effectiveness of nimotuzumab in the treatment of locally advanced and recurrent/metastatic esophageal cancer. This study was conducted to evaluate effectiveness and tolerability of addition of nimotuzumab to conventional treatment in patients with locally advanced or recurrent/metastatic esophageal cancer.


From October 2011 till November 2016, patients with locally advanced or recurrent/metastatic squamous cell carcinoma of esophagus, who were treated with nimotuzumab 200 mg weekly along with conventional therapy at the V. S hospital and cancer center (India), were included. Patients who had received prior targeted therapy were excluded. Effectiveness was evaluated by analyzing tumor response rate and overall survival (OS). All patients were assessed for toxicity and adverse events were reported as per CTCAE v4.03. Statistical analysis was done using STATA.


A total of 15 patients (8 females and 7 males) were analyzed and the median age was 50 years (IQR 45, 50, 67). Majority (53.33%) had lower thoracic esophageal cancer. The tumor response rate observed was as follows: 33% patient had complete response and 67% patients had partial response. The objective response rate was 100%. Survival rate at 1 year, 3 year and 5 year was 58.33%, 29.17% and 29.17%, respectively. Median OS was 26.8 months (95%CI, 2.63- NR). No grade III or grade IV adverse events were observed. No added toxicity was observed due to nimotuzumab.


The study showed that nimotuzumab when combined with conventional treatment in locally advanced or recurrent/metastatic esophageal cancer can achieve improvement in clinical outcomes without producing additional toxicity.

Clinical trial identification

Legal entity responsible for the study

Dr S Subramanian




S. Chaudhari, D. Pawar: Author is employee of Biocon Limited. All other authors have declared no conflicts of interest.